Sugi Predict

Sugi Predict / Compounds / SCHEMBL3392648

SCHEMBL3392648

SCHEMBL3392648

CC(C)(C)OC(=O)N1CCS(=O)(=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HPGD P15428 1/20 0.47
▸ RECQL P46063 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ EPHX2 P34913 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NR1H2 P55055 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9951801 0.93 HPGD (0.50) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL8803621 0.89 USP2 (0.49) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL13812233 0.86 HPGD (0.71) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL15696594 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL6103761 0.84 USP2 (0.56) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL698803 0.83 USP2 (0.69) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL18294 0.83 USP2 (0.69) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL29321415 0.82 USP2 (0.38) USP2SMN1; SMN2HPGDRECQLEPHX1
SCHEMBL13812227 0.82 DDB1 (0.47) HPGDRECQLEPHX1GPR119KDM4E
SCHEMBL18838824 0.82 USP2 (0.50) USP2SMN1; SMN2HPGDRECQLEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 — — US disclosed
CN-117715658-A Method for inhibiting RAS 锐新医药公司 2024-03-15 — — CN disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2023-09-14 — — US disclosed
EP-4192833-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES Richter Gedeon Nyrt. (HU) 2023-06-14 — — EP disclosed
US-11464783-B2 Heterocyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2022-10-11 — — US disclosed
EP-3980406-A1 HETEROCYCLIC COMPOUNDS Aligos Therapeutics, Inc. (US) 2022-04-13 — — EP disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 — — US disclosed
CN-1678607-A Nitrogen-containing aromatic ring derivatives EISAI CO LTD (JP) 2005-10-05 — — CN disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 — — EP disclosed
EP-1015449-B1 (HETERO)ARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS FACTOR XA INHIBITORS ASTRAZENECA AB (SE) 2005-01-05 — — EP disclosed
EP-0979240-B1 SERINE PROTEASE INHIBITORS AKZO NOBEL NV (NL) 2004-04-14 — — EP disclosed
US-6534495-B1 Anticoagulants that prevent thrombin-related diseases. AKZO NEBEL (NL) 2003-03-18 — — US disclosed
US-6486154-B1 (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors ZENECA LIMITED (GB) 2002-11-26 — — US disclosed
EP-1015449-A1 (HETERO)ARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS FACTOR XA INHIBITORS AstraZeneca UK Limited (GB) 2000-07-05 — — EP disclosed
EP-0979240-A1 SERINE PROTEASE INHIBITORS Akzo Nobel N.V. (NL) 2000-02-16 — — EP disclosed
WO-1999009027-A1 (HETERO)ARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS FACTOR XA INHIBITORS ZENECA LIMITED (GB) 1999-02-25 — — WO disclosed
WO-1998050420-A1 SERINE PROTEASE INHIBITORS AKZO NOBEL N.V. (NL) 1998-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11464783-B2 Heterocyclic compounds SLC10A1, CFTR, PKD1 USP2 4623/4885SMN1; SMN2 468/4885HPGD 282/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP USP2 2385/4885SMN1; SMN2 2473/4885HPGD 1673/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP USP2 2309/4885SMN1; SMN2 2327/4885HPGD 1675/4885
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 USP2 2291/4885SMN1; SMN2 4785/4885HPGD 987/4885
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES GABRA5, GABRA1, P2RX5 USP2 4591/4885SMN1; SMN2 2384/4885HPGD 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.